Expression of androgen receptor and growth factors in premalignant lesions of the prostate

Journal of Pathology

Volumn 186, Issue 2, 1998, Pages 169-177

  Harper, Maureen E ^a,b   Glynne Jones, Eve ^a   Goddard, Lindy ^a   Mathews, Phillip ^a   Nicholson, Robert I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Tenovus Inst Cancer Res   (United Kingdom)

Author keywords

AAH; Androgen receptor; C erbB 2; EGF receptor; FGF 2; PIN; Prostate cancer; TGF a; VEGF

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; KERATIN; TRANSFORMING GROWTH FACTOR ALPHA; UVOMORULIN; VASCULOTROPIN;

ARTICLE; CELL PROLIFERATION; HISTOPATHOLOGY; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RECEPTOR BINDING;

ANTIGENS, NUCLEAR; CADHERINS; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 2; GROWTH SUBSTANCES; HUMANS; KI-67 ANTIGEN; LYMPHOKINES; MALE; NUCLEAR PROTEINS; PRECANCEROUS CONDITIONS; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; TRANSFORMING GROWTH FACTOR ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031714004     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(1998100)186:2<169::AID-PATH164>3.0.CO;2-W     Document Type: Article

References (30)

1. McNeil JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986; 17: 64-71.
2. Bostwick DG, Brawer MK. Prostatic intraepithelial neoplasia and early invasion in prostatic carcinoma. Cancer 1987; 59: 788-794.
3. Bostwick DG, Pacelli A, Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate 1996; 29: 117-134.
4. Epstein JI. Adenosis (atypical adenomatous hyperplasia): histopathology and relationship to carcinoma. Pathol Res Pract 1995; 191: 888-898.
5. Bostwick DG, Srigley J, Grignon D, et al. Atypical adenomatous hyperplasia of the prostate: morphological criteria for its distinction from well differentiated carcinoma. Hum Pathol 1993; 24: 819-832.
6. Helpap BGT, Bostwick DG, Montironi R. The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostatic carcinoma. Virchows Arch 1995; 426: 425-434.
7. Helpap BG. Cell kinetic studies on prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia (AAH) of the prostate. Pathol Res Prac 1995; 191: 904-907.
8. Myers RB, Srivastava S, Oelschalager DK, Grizzle WE. Expression of p160 erbB-3 and p185 erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinomas. J Natl Cancer Inst 1994; 86: 1140-1145.
9. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspective. Endocrine Rev 1995; 16: 271-321.
10. Van De Kwast ThH, TeTu B. Androgen receptors in untreated and treated prostatic intraepithelial neoplasia. Eur Urol 1996; 30: 265-268.
11. Maygarden SJ, Strom S, Ware JL. Localisation of epidermal growth factor receptor by immunocytochemical methods in human prostatic carcinoma. prostatic intraepithelial neoplasia, and benign hyperplasia. Arch Pathol Lab Med 1992; 116: 267-273.
12. Roberson CN, Roberson KM, Herzberg AJ, Kerns B-JM, Dodges RK, Paulson DF. Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostate tissues. Surg Oncol 1994; 3: 237-242.
13. Harper ME, Goddard L, Glynne-Jones E, Peeling WB, Griffiths K. Epidermal growth factor expression by northern analysis and immunohistochemistry in benign and malignant prostatic tumours. Eur J Cancer 1995; 31: 1492-1497.
14. Harper ME, Goddard L, Glynne-Jones E, et al. An immunocytochemical analysis of TGFα expression in benign and malignant prostatic tumors. Prostate 1993; 23: 9-23.
15. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
16. Montironi R, Magi Galluzzi C, Diamonti L. Prostatic intraepithelial neoplasia. Qualitative and quantitative analysis of blood capillary architecture on thin tissue sections. Pathol Res Pract 1993; 189: 542-548.
17. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-447.
18. Zagzag D. Angiogenic growth factors in neural embryogenesis and neoplasia. Am J Pathol 1995; 146: 293-309.
19. Story MT. Regulation of prostate growth by fibroblast growth factors. World J Urol 1995; 13: 297-305.
20. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K. Vascular endothelial growth factor expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 1996; 74: 910-916.
21. Umbras R, Issacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostatic carcinoma. Cancer Res 1994; 54: 3929-3933.
22. Bostwick DG. Origins of prostate carcinoma. Cancer 1996; 78: 230-236.
23. Botticelli AR. A theoretical rationale on the hislogenesis of premalignant lesions and early carcinoma of the prostate. Pathologica 1994; 86: 128-141.
24. Bonkoff H, Stein U, Remberger K. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 1994; 24: 114-118.
25. Fox JC, Shanley JR. Antisense inhibition of basic fibroblast growth factor induces apoptosis in vascular smooth muscle cells. J Biol Chem 1996; 271: 12 578-12 584.
26. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16: 5276-5287.
27. Silver RI, Wiley EL, Thigpen AE, Guileyardo JM, McConnell JD, Russell DW. Cell type specific expression of steroid 5 alpha-reductase 2. J Urol 1994; 152: 438-442.
28. Kuil CW, Brinkmann AO. Androgens, antiandrogens and androgen receptor abnormalities. Eur Urol 1996; 29 (Suppl 2): 78-82.
29. Sherwood ER, Lee C. Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. World J Urol 1995; 13: 290-296.
30. Fox SB, Persad RA, Coleman N, Day CA, Silcocks PB, Collins CC. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic cancer. Br J Urol 1994; 74: 214-220.